Use of mPEG-PLGA nanoparticles to improve bioactivity and hemocompatibility of streptokinase: In-vitro and in-vivo studies.

摘要: Abstract Streptokinase, a clot-dissolving agent, is widely used in treatment of cardiovascular diseases such as blood clots and deep thrombosis. Streptokinase cost-effective drug with short biological half-life (i.e. 15 to 30 min). In addition, due its prokaryotic source, the immune response quickly reacts drug. Despite these limitations, streptokinase still first choice for associated this work, was encapsulated mPEG-PLGA nanoparticles improve pharmacokinetic properties. The containing enzyme were prepared by coaxial electrospray their physicochemical properties, compatibility, circulation time cell toxicity evaluated. results showed that use encapsulate resulted prolonged (up 120 min) slight decrease activity. vivo studies also did not have adverse effect on biochemistry parameters well liver kidney tissues. As result, potential increasing activity no important effect.